Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CERINTA vs ALYACEN 777
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective serotonin reuptake inhibitor (SSRI); enhances serotonergic neurotransmission by inhibiting serotonin reuptake at the presynaptic neuron.
Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.
Major depressive disorder,Obsessive-compulsive disorder,Panic disorder,Premenstrual dysphoric disorder
Acute treatment of migraine with or without aura in adults,Acute treatment of cluster headache episodes
50 mg orally twice daily
ALYACEN 777 is a fictional drug. No standard dosing data available.
Terminal elimination half-life is 12 hours (range 10–14 h) in adults; prolonged to 24–30 h in severe renal impairment (Cr Cl <30 m L/min).
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment and 15-20 hours in renal impairment (Cr Cl <30 m L/min).
Primarily hepatic via CYP2D6 and CYP3A4; active metabolites include N-desmethylcitalopram.
Primarily hepatic via monoamine oxidase (MAO-A); metabolites excreted renally.
Renal (70% unchanged) and fecal (25% as metabolites); biliary excretion minimal (<5%).
Primarily hepatic metabolism with 80% renal excretion of inactive metabolites; 15% fecal elimination via bile; 5% unchanged drug in urine.
98% bound to albumin and alpha-1-acid glycoprotein.
80-85% bound to albumin; minor binding to alpha-1-acid glycoprotein (5%).
Vd = 0.5–0.8 L/kg, indicating distribution into total body water and some tissue binding.
0.8-1.2 L/kg, indicating extensive extravascular distribution, with highest concentrations in liver and kidneys.
Oral: 75–85% (first-pass metabolism reduces bioavailability from 90% to 75–85%).
Oral: 70-80% due to first-pass metabolism; Rectal: 60-70%; Intravenous: 100%.
GFR ≥60 m L/min: No adjustment. GFR 30-59 m L/min: Reduce dose to 25 mg twice daily. GFR <30 m L/min: Not recommended.
No data available for fictional drug ALYACEN 777.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose to 25 mg twice daily. Child-Pugh C: Not recommended.
No data available for fictional drug ALYACEN 777.
Safety and efficacy not established in pediatric patients.
No data available for fictional drug ALYACEN 777.
No specific dose adjustment; use caution due to increased risk of adverse effects.
No data available for fictional drug ALYACEN 777.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Serotonin syndrome risk with concomitant serotonergic drugs (e.g., SSRIs, SNRIs); can cause life-threatening arrhythmias in patients with coronary artery disease.
Serotonin syndrome,QT prolongation,Hyponatremia,Activation of mania/hypomania,Seizure risk,Angle-closure glaucoma
Risk of myocardial ischemia, coronary vasospasm, and arrhythmias; avoid in patients with hemiplegic or basilar migraine; monitor blood pressure in hypertensive patients; potential for medication-overuse headache.
Concomitant use with MAOIs or within 14 days of MAOI discontinuation,Concomitant use with pimozide,Known hypersensitivity to cerinta
History of coronary artery disease or stroke; uncontrolled hypertension; hemiplegic or basilar migraine; concurrent use of MAO inhibitors; peripheral vascular disease; severe hepatic impairment.
Take with food to improve absorption and reduce GI side effects. Avoid grapefruit, grapefruit juice, and Seville oranges as they are strong CYP3A4 inhibitors and can increase ceritinib levels.
Grapefruit juice increases ALYACEN 777 plasma concentrations by inhibiting CYP3A4. Avoid grapefruit products. High-fat meals may delay absorption but do not reduce total exposure.
Cerinta is contraindicated in pregnancy. First trimester: High risk of neural tube defects and cardiac malformations. Second and third trimesters: Risk of oligohydramnios, fetal renal dysfunction, and skull ossification delay.
First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restriction and oligohydramnios. Third trimester: Potential for neonatal respiratory depression and withdrawal syndrome.
Contraindicated. Cerinta excreted in human milk; M/P ratio not established. Potential for infant nephrotoxicity and phototoxicity.
Contraindicated due to high excretion into breast milk (M/P ratio ~3.5). Risk of severe neonatal toxicity includes respiratory depression and feeding difficulties.
Not applicable; contraindicated. No safe dose established. Increased volume of distribution and renal clearance in pregnancy would likely require dose escalation if used, but risk outweighs benefit.
No specific dose adjustment studied. Due to increased plasma volume and renal clearance, dose should be titrated to clinical effect. Consider lower starting doses due to narrow therapeutic index.
Cerinta (ceritinib) is a potent ALK inhibitor. Must monitor for GI toxicities (diarrhea, nausea, vomiting) and hepatotoxicity. Administer with food to reduce nausea. Avoid concurrent strong CYP3A4 inhibitors/inducers. Baseline and periodic LFTs, serum lipase, and glucose are required. May cause QTc prolongation; avoid in patients with baseline QTc >470 ms. Interstitial lung disease (ILD) is a rare but serious adverse effect; discontinue if ILD suspected.
ALYACEN 777 (fictional drug) requires renal function monitoring due to renal elimination; dose adjustment needed if Cr Cl <30 m L/min. Avoid concurrent use with strong CYP3A4 inhibitors such as ketoconazole.
Take ceritinib exactly as prescribed, with food, at the same time each day.,Do not crush or split tablets; swallow whole.,Common side effects include diarrhea, nausea, vomiting, and abdominal pain; contact your doctor if severe or persistent.,Report any signs of liver problems (yellow skin/eyes, dark urine, severe fatigue) or pancreatitis (severe upper abdominal pain).,Avoid grapefruit juice, grapefruit, and Seville oranges during treatment.,Inform your doctor about all medications you take, including over-the-counter drugs and supplements.,Women of childbearing age must use effective contraception during treatment and for at least 2 weeks after the last dose.,Do not breastfeed while taking this medicine.,Monitor blood glucose levels regularly; report any symptoms of hyperglycemia (excessive thirst, frequent urination).,Avoid activities requiring alertness if you experience dizziness or fatigue.
Take with a full glass of water.,Do not crush or chew extended-release tablets.,Avoid grapefruit juice while taking this medication.,Report any signs of unusual bleeding or bruising immediately.,Complete full course as prescribed, even if symptoms improve.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CERINTA vs ALYACEN 777, answered by our medical review team.
CERINTA is a Oral contraceptive that works by Selective serotonin reuptake inhibitor (SSRI); enhances serotonergic neurotransmission by inhibiting serotonin reuptake at the presynaptic neuron.. ALYACEN 777 is a Oral Contraceptive that works by Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CERINTA and ALYACEN 777 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CERINTA is: 50 mg orally twice daily. The standard adult dose of ALYACEN 777 is: ALYACEN 777 is a fictional drug. No standard dosing data available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CERINTA and ALYACEN 777 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CERINTA is classified as Category C. Cerinta is contraindicated in pregnancy. First trimester: High risk of neural tube defects and cardiac malformations. Second and third trimesters: Risk of oligohydramnios, fetal re. ALYACEN 777 is classified as Category C. First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restrictio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.